Allotment of 6,25,000 Equity Shares and 29,50,000 Warrants on preferential basis under SEBI (ICDR) Regulations, 2018 through Circulation on Tuesday, 24th February, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Eiko Lifesciences has allotted 6,25,000 equity shares at Rs. 55 each (face value Rs. 10, premium of Rs. 45), raising about Rs. 3.44 crore. It has also allotted 29,50,000 convertible warrants at the same Rs. 55 price, which on full conversion would bring in another Rs. 16.22 crore, with 25% (Rs. 4.06 crore) received upfront. Most allottees are from the promoter and promoter group — Bhavesh Dhirajlal Tanna (promoter) and Lenus Finvest Pvt Ltd (promoter group) — along with three non-promoter allottees including V Square Pharmachem Pvt Ltd. The shares will rank equally with existing equity shares. BSE has already given in-principle approval for the issue.
The preferential issue is promoter-led, signalling insider confidence, but full conversion of warrants would meaningfully expand the share count and dilute existing shareholders. The Rs. 55 pricing at a premium to face value suggests the company raised funds without distress pricing.